IVUS- guided PCI Reduces One-Year Target Vessel Failure vs Angiography -guided PCI in Complex Bifurcation PCI: DKCRUSH VIII Trial
Key Points Intravascular imaging has been increasingly recognized as a cornerstone of contemporary percutaneous coronary intervention, particularly for complex coronary... Read more.
IVUS-guided PCI was Not Associated with Lower Risk of Target-Vessel Failure vs Angiography-guided PCI alone in Complex High-Risk PCI: IVUS-CHIP Trial
Key Points Intravascular ultrasound guidance during percutaneous coronary intervention has been associated with improved stent optimization and reduced adverse events... Read more.
Asundexian Associated with an Impressive 26% Reduction in Recurrent Stroke Without Increased Bleeding. The OCEANIC-STROKE trial
Asundexian is a direct, potent small molecule inhibitor of Factor XIa (FXIa). Previously, in a randomized, placebo-controlled, double-blind, dose-finding trial of... Read more.
NOAC Monotherapy Non-Inferior to Combination Therapy for Net Adverse Clinical events in AF Patients Post–DES: ADAPT AF-DES Trial
Key Points The ADAPT AF-DES randomized trial compared NOAC monotherapy (apixaban or rivaroxaban) versus NOAC plus clopidogrel in atrial fibrillation (AF) patients... Read more.
Prasugrel Might be a Better Choice than Ticagrelor For DAPT after PCI for Patients with Diabetes and MVD: The TUXEDO-2 Trial
Key Points TUXEDO-2 directly compared ticagrelor vs prasugrel based DAPT in 1,800 patients with diabetes and multivessel coronary artery disease (MVD) undergoing... Read more.
Two Factor XI Antibodies For the Prevention of Post- operative VTE: Results from ROXI-VTE-I and ROXI-VTE-II Trials
Key Points: ROXI-VTE-I and ROXI-VTE-II evaluated two distinct factor XI monoclonal antibodies REGN9933A2 and REGN7508Cat, for prevention of venous thromboembolism... Read more.
Dapagliflozin Reduced LVMI in Patients with CKD : DECODE-CKD
Key Points The DECODE-CKD trial investigated the effects of SGLT-2 inhibitor Dapagliflozin on cardiac structure and function in patients with chronic kidney disease... Read more.
Benefit from Intensive BP Control Across Frailty Statuses – A Post-Hoc Analysis of ESPRIT trial
Key Points The ESPRIT trial assessed whether the efficacy and safety of intensive blood pressure (BP) varies across frailty status compared to control. In this open-label... Read more.